| 5.66 -0.36 (-5.98%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.75 | 1-year : | 9.05 |
| Resists | First : | 6.63 | Second : | 7.75 |
| Pivot price | 5.84  |
|||
| Supports | First : | 4.97 | Second : | 3.94 |
| MAs | MA(5) : | 5.83 |
MA(20) : | 5.56 |
| MA(100) : | 6.24 |
MA(250) : | 9.7 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.6 |
D(3) : | 60.4 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 18 | Low : | 3.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IMA ] has closed above bottom band by 14.2%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.22 - 6.25 | 6.25 - 6.28 |
| Low: | 5.58 - 5.61 | 5.61 - 5.64 |
| Close: | 5.6 - 5.66 | 5.66 - 5.71 |
C
Thu, 30 Apr 2026
IMA SEC Filings - ImageneBio 10-K, 10-Q, 8-K Forms - Stock Titan
Thu, 30 Apr 2026
IMA Price Today: ImageneBio, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Thu, 30 Apr 2026
ImageneBio (NASDAQ: IMA) plans 2026 virtual meeting and equity plan vote - Stock Titan
Wed, 29 Apr 2026
IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally? - MSN
Wed, 29 Apr 2026
OrbiMed adds pre-funded warrants in ImageneBio (IMA) 2026 PIPE - Stock Titan
Tue, 28 Apr 2026
Short Interest in ImageneBio, Inc. (NASDAQ:IMA) Increases By 51.7% - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.27e+006 (%) |
| Held by Institutions | 15.8 (%) |
| Shares Short | 379 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.805e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 56.3 % |
| Return on Equity (ttm) | -35.9 % |
| Qtrly Rev. Growth | 800000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -9.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 378160 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|